ETHOSUXIMIDE
Clinical safety rating: caution
Animal studies have proved adverse effects but may be safe for humans
Ethosuximide reduces the frequency of spike-and-wave discharges in absence seizures by blocking T-type calcium channels in thalamic neurons, thereby stabilizing neuronal membrane and preventing rhythmic burst firing.
| Metabolism | Primarily metabolized by hepatic microsomal enzymes, including CYP3A4 and CYP2E1, with about 80% excreted in urine as metabolites and 20% as unchanged drug. |
| Excretion | Primarily renal excretion; ~20% as unchanged ethosuximide and ~50% as conjugated metabolite (glucuronide plus minor hydroxymetabolites). Less than 5% eliminated via feces. |
| Half-life | Terminal elimination half-life is approximately 60 hours (range 40–60 hours) in adults; children may have shorter half-life (~30–40 hours). Long half-life allows once- or twice-daily dosing. |
| Protein binding | Plasma protein binding: ~10–20%; primarily binds to albumin. |
| Volume of Distribution | Volume of distribution: approximately 0.7 L/kg (range 0.5–1.0 L/kg). This indicates distribution throughout total body water. |
| Bioavailability | Oral bioavailability: >90% (essentially complete absorption). |
| Onset of Action | Oral: Clinical effect typically begins within 3–7 days; steady state achieved in ~8–12 days (4–5 half-lives). |
| Duration of Action | Duration of action is approximately 24–48 hours due to long half-life; once-daily dosing maintains therapeutic concentrations. |
Adults: 500 mg orally twice daily initially, increase by 250 mg every 4-7 days as needed; maintenance dose 1-2 g/day divided into 2-4 doses. Maximum 1.5 g/dose or 3 g/day.
| Dosage form | CAPSULE |
| Renal impairment | GFR <10 mL/min: Use with caution, consider dose reduction. No specific GFR-based guidelines; monitor for toxicity. Hemodialysis: Supplement 250 mg post-dialysis. |
| Liver impairment | No specific Child-Pugh based guidelines. Use with caution in severe hepatic impairment; monitor liver function tests. |
| Pediatric use | Children 3-6 years: 250 mg orally once daily initially; increase by 250 mg every 4-7 days; maintenance 20-40 mg/kg/day divided into 2-4 doses. Children ≥6 years: same as adult. |
| Geriatric use | Start at lower end of dosing range due to age-related decreased clearance; monitor renal function and neurological status. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
CNS depressants may enhance sedative effects Can cause blood dyscrasias including aplastic anemia and SLE.
| Breastfeeding | Excreted into human breast milk; milk-to-plasma ratio approximately 0.8. Infant serum levels are low (subtherapeutic) but may cause sedation, poor suckling, or allergic reactions. Use with caution, monitor infant for drowsiness and weight gain; benefit of breastfeeding likely outweighs minimal risk. |
| Teratogenic Risk | First trimester: Increased risk of major congenital malformations, particularly neural tube defects and cleft palate, based on limited human data; animal studies show embryotoxicity. Second and third trimesters: Risk of fetal anticonvulsant syndrome including growth retardation, microcephaly, and cognitive impairment; no evidence of specific major malformations from later exposure. |
■ FDA Black Box Warning
No FDA black box warning.
| Common Effects | Drowsiness |
| Serious Effects |
["Hypersensitivity to ethosuximide or succinimides","Concurrent use with other succinimides (cross-sensitivity)"]
| Precautions | ["Suicidal ideation and behavior: Increased risk of suicidal thoughts or actions; monitor for depression and mood changes.","Blood dyscrasias: Rare cases of agranulocytosis, pancytopenia, and leukopenia; monitor blood counts periodically.","Systemic lupus erythematosus (SLE): May exacerbate or induce SLE; discontinue if symptoms appear.","Withdrawal: Abrupt discontinuation may precipitate absence seizure status; taper gradually.","Renal/hepatic impairment: Use with caution in patients with hepatic or renal disease."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum ethosuximide levels at least once per trimester and after dose adjustments; therapeutic range 40-100 mcg/mL. Fetal ultrasound for anatomy at 18-20 weeks gestation. Neonatal monitoring for withdrawal symptoms (irritability, feeding difficulties) and coagulation abnormalities if used with other anticonvulsants; maternal folate supplementation recommended. |
| Fertility Effects | Limited human data; ethosuximide may reduce fertility in animal studies. In women, no significant impact on ovulation or hormonal profiles reported; however, underlying epilepsy may affect fertility. In men, no adverse effects on spermatogenesis documented. |